Ignite Creation Date:
2025-12-24 @ 3:40 PM
Ignite Modification Date:
2025-12-25 @ 1:50 PM
Study NCT ID:
NCT02321592
Status:
COMPLETED
Last Update Posted:
2020-11-13
First Post:
2014-12-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Sponsor:
University of Cologne
Organization:
Study Overview
Official Title:
GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GHSG-AFM13
Brief Summary:
The study is designed
* to demonstrate efficacy of AFM13 with an optimized treatment schedule
* to decide whether AFM13 warrants further investigation in a phase III clinical trial
* to demonstrate efficacy of AFM13 with an optimized treatment schedule
* to decide whether AFM13 warrants further investigation in a phase III clinical trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2014-004036-19 | EUDRACT_NUMBER | None | View |